Abstract
Background: Non-small cell lung cancer (NSCLC) is the leading cause of cancer mortality worldwide. At present no reliable biomarkers are available to guide the management of this condition. Microarray technology may allow appropriate biomarkers to be identified but present platforms are lacking disease focus and are thus likely to miss potentially vital information contained in patient tissue samples.
Original language | English |
---|---|
Pages (from-to) | 20-25 |
Number of pages | 6 |
Journal | BMC Medical Genomics |
Volume | 1 |
DOIs | |
Publication status | Published - 2008 |
Fingerprint
Dive into the research topics of 'Generation of a non-small cell lung cancer transcriptome microarray'. Together they form a unique fingerprint.Impacts
-
Development and Commercialization of a Technology Platform to Enable Biomarker Discovery and Validation
Richard Kennedy (Participant), Denis Harkin (Participant), Patrick Johnston (Participant), Alison Hosey (Participant), Julia Miskelly (Participant), Margaret Murray (Participant), Jennifer Quinn (Participant), Colin James (Participant), Jude Mulligan (Participant), Peter Daly (Participant), Paul Mullan (Participant), Julie Mussen (Participant), Ultan McDermott (Participant), Richard Wilson (Participant) & Daniel Longley (Participant)
Impact: Health Impact, Quality of Life Impact